Thomas Thorson, MD
Family Medicine · Mandan, NDNPI 1942308614
Payments from drug & device makers
Across 556 payments — averaging $433.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$200K
- Shire North American Group Inc$34K
- AstraZeneca$1K
- AbbVie$1K
- Lilly USA, LLC$1K
- Amgen$479
- plus $3K from 25 others
What the payments were for
- Consulting fees$233,95097%
- Food & beverage$6,9213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 88 | $200,392 |
| Shire North American Group Inc | 12 | $33,800 |
| AstraZeneca | 24 | $1,170 |
| AbbVie(2 entities) | 78 | $1,104 |
| Lilly USA, LLC | 93 | $1,043 |
| Amgen | 36 | $479 |
| Pfizer | 31 | $370 |
| Boehringer Ingelheim | 34 | $370 |
| Novo Nordisk | 22 | $305 |
| Astellas Pharma US Inc | 17 | $271 |
| Novartis | 15 | $244 |
| GSK | 37 | $211 |
| Johnson & Johnson | 12 | $172 |
| Merck | 9 | $135 |
| Bayer | 8 | $121 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Madrigal Pharmaceuticals | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Alkermes, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$240,871 in reported general payments places this provider in the 95th percentile of 337 family medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 125 | $90,014 |
| EliquisApixaban | 94 | $72,068 |
| OzempicSemaglutide | 74 | $69,356 |
| TrulicityDulaglutide | 59 | $68,487 |
| FarxigaDapagliflozin Propanediol | 38 | $30,299 |
| XareltoRivaroxaban | 39 | $29,547 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $27,565 |
| JanuviaSitagliptin Phosphate | 43 | $26,276 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $23,033 |
| Repatha SureclickEvolocumab | 33 | $18,030 |
| TradjentaLinagliptin | 21 | $13,594 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,442 |
| MounjaroTirzepatide | 15 | $11,133 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 34 | $10,184 |
| Bydureon BciseExenatide Microspheres | 12 | $9,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Spiriva Respimat, Jentadueto | $370 | $145,540219 claims |
| PfizerEliquis, Abrysvo | $370 | $82,253128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,043 | $79,62074 claims |
| Novo NordiskOzempic | $305 | $69,35674 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,170 | $43,74158 claims |
| MerckJanuvia, Dulera | $135 | $31,49760 claims |
| Johnson & JohnsonXarelto | $172 | $29,54739 claims |
| GSKIncruse Ellipta | $211 | $4,17912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 family medicine providers in North Dakota.
Other family medicine in Mandan
- Anthony JohnsonMandan$7K
- Dale KleinMandan$3K
- Gretchen Belzer CurlMandan$3K
- Meghan HendricksonMandan$3K
- Sadaf YousufMandan$1K
- Andrew DockterMandan$983
- Swarna YadlapalliFargo$2.9M
- Joel SchockFargo$1.2M
- Hoadley HarrisFargo$830K
- Richard VetterWest Fargo$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.